Bridging the gap between a TB drug and its target

Gregory M Cook; Adam Heikal

doi:10.1126/scitranslmed.3004816

Bridging the gap between a TB drug and its target

Sci Transl Med. 2012 Sep 5;4(150):150fs33. doi: 10.1126/scitranslmed.3004816.

Authors

Gregory M Cook¹, Adam Heikal

Affiliation

¹ Department of Microbiology and Immunology, Otago School of Medical Sciences, University of Otago, Post Office Box 56, Dunedin 9054, New Zealand. gregory.cook@otago.ac.nz

PMID: 22956196
DOI: 10.1126/scitranslmed.3004816

Abstract

A promising new TB drug cocrystallized with its mycobacterial target provides a platform for structure-based design that will improve TB drug development (Neres et al.).

Publication types

Comment

MeSH terms

Antitubercular Agents / chemistry*
Antitubercular Agents / pharmacology*
Microbial Viability / drug effects*
Mycobacterium tuberculosis / drug effects*
Thiazines / chemistry*
Thiazines / pharmacology*

Substances

Antitubercular Agents
Thiazines